Molecularly targeted therapy using bevacizumab for non-small cell lung cancer: A pilot study for the new ct response criteria

Korean Journal of Radiology

Volumn 11, Issue 6, 2010, Pages 618-626

  Lee, Ho Yun ^a   Lee, Kyung Soo ^a   Hwang, Hye Sun ^a   Lee, Ju Won ^a   Ahn, Myung Ju ^a   Park, Keunchil ^a   Kim, Tae Sung ^a   Yi, Chin A ^a   Chung, Myung Jin ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Guideline; Non small cell lung cancer; Response criteria; Targeted therapy; Tumor response assessment

Indexed keywords

BEVACIZUMAB; CISPLATIN; GEMCITABINE; IOMEPROL;

ADULT; ARTICLE; CANCER GROWTH; CANCER SIZE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; LUNG NON SMALL CELL CANCER; MALE; MOLECULARLY TARGETED THERAPY; OBSERVER VARIATION; OUTCOME ASSESSMENT; PILOT STUDY; PREDICTION; PROGNOSIS; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PILOT PROJECTS; PROGNOSIS; RADIOGRAPHIC IMAGE INTERPRETATION, COMPUTER-ASSISTED; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 78449266351     PISSN: 12296929     EISSN: None     Source Type: Journal    
DOI: 10.3348/kjr.2010.11.6.618     Document Type: Article

References (11)

1. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216
2. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-247
3. Crabb SJ, Patsios D, Sauerbrei E, Ellis PM, Arnold A, Goss G, et al. Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer. J Clin Oncol 2009;27:404-410
4. Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007;25:1753-1759
5. Stacchiotti S, Collini P, Messina A, Morosi C, Barisella M, Bertulli R, et al. High-grade soft tissue sarcomas: tumor response assessment--pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria. Radiology 2009;251:447-456
6. Lee HY, Han J, Lee KS, Koo JH, Jeong SY, Kim BT, et al. Lung adenocarcinoma as a solitary pulmonary nodule: prognostic determinants of CT, PET, and histopathologic findings. Lung Cancer 2009;66:379-385
7. Curran SD, Muellner AU, Schwartz LH. Imaging response assessment in oncology. Cancer Imaging 2006;6:S126-S130
8. Gwyther SJ. Current standards for response evaluation by imaging techniques. Eur J Nucl Med Mol Imaging 2006;33:11-15
9. Ratain MJ, Eckhardt SG. Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. J Clin Oncol 2004;22:4442-4445
10. Sabir A, Schor-Bardach R, Wilcox CJ, Rahmanuddin S, Atkins MB, Kruskal JB, et al. Perfusion MDCT enables early detection of therapeutic response to antiangiogenic therapy. AJR Am J Roentgenol 2008;191:133-139
11. Kan Z, Phongkitkarun S, Kobayashi S, Tang Y, Ellis LM, Lee TY, et al. Functional CT for quantifying tumor perfusion in antiangiogenic therapy in a rat model. Radiology 2005;237:151-158